Compare top Glioblastoma doctors and prices in Germany. Find your best match here.
We'll hand-pick the best doctors based on your needs and budget.
Meet the experts behind this page
Medically reviewed by Fahad Mawlood
Medical Editor & Data ScientistTop doctors
2
Germany
Reviews
14,000+
From real patients
Get free personalized treatment plans and choose the best option. No commitment · No payments for our services
Show first:
Prof. Vajkoczy leads the Neurosurgery Department at Charité – Universitätsmedizin Berlin, performing over 4,000 neurosurgeries annually.
Prof. Jürgen Kiwit is a top German neurosurgeon specializing in minimally invasive brain tumor surgeries at Meoclinic Berlin.
Choosing a clinic abroad can be stressful. At Bookimed, with over 800K patients helped, we understand your concerns. We know how to find trusted doctors, the best price-quality options, and solutions for even complex cases. We’re here to guide you every step of the way.
Yan Matsiivskiy
Head of Medical Coordinator Team
4300++ patient journeys guided
3 years at Bookimed
1022 patients from Germany have found their doctor through us this month
2 min Quiz
Tell us your goal, budget, timeline
Human Matching + AI
Our algorithm finds matches, coordinator verifies fit
Your Options Ready
Compare prices, packages, dates. Chat with your coordinator
Overwhelmed by choices?
Guiding your treatment
Medically trained personal coordinators
| Rank | Doctor | experience | Good Fit For | What Sets Them Apart | Clinic & Location | Consultation |
|---|---|---|---|---|---|---|
| #1 | 31 years of experience | Complex brain tumor cases | Leads one of Europe's busiest neurosurgery departments – pioneers in brain tumor and vascular disorder treatments. Award-winning researcher in microcirculation. | Germany | Price on request
| |
| #2 | 35 years of experience | Minimally invasive brain tumor surgeries | Specializes in glioma therapy and complex brain surgeries. Head of Neurosurgery Department at Meoclinic Berlin. Member of American Association of Neurological Surgeons. | Germany | from
$300 |
German neuro-oncology centers offer a multimodal approach combining microsurgical resection, radiation, and chemotherapy. Advanced options include 5-ALA fluorescence-guided surgery to identify tumor margins and Tumor Treating Fields. Personalized immunotherapies like dendritic cell vaccines and CAR T-cell therapy are also accessible at specialized university clinics.
Bookimed Expert Insight: While many focus on surgery, the integration of molecular diagnostics like MGMT methylation testing is vital. Clinics like Nordwest and Charité Berlin use these markers to predict chemotherapy response. This data-driven approach allows doctors to switch to advanced therapies like Actinium-225 or CAR-T earlier if standard drugs show low efficacy.
Patient Consensus: Patients often emphasize that the initial surgery is just the first step. They note that having access to Optune devices and local specialists who coordinate long-term follow-up care simplifies the complex journey.
Germany houses world-leading neuro-oncology centers like Charite Berlin and University Hospital Heidelberg. These facilities utilize multidisciplinary tumor boards and advanced neurosurgery. Specialized academic centers offer high-precision therapies and active clinical trials. They maintain rigorous German Cancer Society certifications for glioblastoma care quality.
Bookimed Expert Insight: While major centers like Charite Berlin serve over 800,000 patients yearly, experience depth varies by surgeon. Prof. Dr. Med. Peter Vajkoczy at Charite personally performs 4,000 operations annually. This high individual volume often correlates with better outcomes in complex glioma resections. Patients should prioritize doctors with designated Focus magazine top-tier rankings for neuro-oncology.
Patient Consensus: Patients emphasize finding centers with active clinical trials and insist on molecular profiling like MGMT and IDH markers. Many note that intraoperative MRI systems significantly improve resection results compared to standard surgical methods.
Contemporary German glioblastoma therapy protocols achieve median overall survival between 15 and 21 months for newly diagnosed cases. Specialized centers utilize multi-modal approaches. These combine surgical resection with temozolomide chemotherapy and radiotherapy. Patients with MGMT methylation often reach 24 or more months with tumor-treating fields.
Bookimed Expert Insight: German neuro-oncology differentiates itself through massive patient volume and research integration. Charité - Universitätsmedizin Berlin treats over 845,000 patients annually. This scale allows clinics like Medical Center in Solingen to maintain German Cancer Society certification. Our data shows that top German neurosurgeons often perform 4,000+ surgeries yearly. This high frequency creates a proficiency gap that stabilizes survival outcomes even in complex recurrences.
Patient Consensus: Patients emphasize the importance of early genetic testing for MGMT and IDH markers to guide treatment. Many note that maintaining strict compliance with wearable therapies like Optune is essential for hitting the 2-year survival mark.
Dendritic cell therapy uses a personalized vaccine to train the immune system to recognize glioblastoma cells. This autologous treatment involves extracting patient monocytes, maturing them with tumor antigens in a laboratory, and re-injecting them to trigger a targeted T-cell response against remaining brain cancer cells.
Bookimed Expert Insight: Data suggests combining dendritic cell therapy with specialized surgical centers increases effectiveness. Prof. Dr. Peter Vajkoczy at Charité performs over 4,000 surgeries annually, ensuring the low tumor burden required for immunotherapy success. Leading centers like Nordwest Clinic utilize Focus-listed specialists like Prof. Elke Jäger to pioneer these therapeutic individual antitumor vaccines.
Patient Consensus: Patients emphasize that this therapy works best after maximal safe surgery rather than as a standalone treatment. Many note that while infusions are easy to tolerate, regular MRI monitoring every 3 months is essential to track stability.
German oncology centers determine candidacy for CAR-T and monoclonal antibody trials through molecular profiling and physical assessment. Patients typically require confirmed glioblastoma recurrence after standard therapy and a Karnofsky performance status above 70%. Eligibility also depends on specific biomarkers like MGMT methylation or EGFR expression.
Bookimed Expert Insight: Data from top German university hospitals like Charité and Dusseldorf shows that genomic profiling is the most critical hurdle. About 80% of glioblastoma patients may find their tumors lack the specific proteins required for current CAR-T targets. Contacting a center with an integrated research institute, such as Nordwest Clinic with its 5 research branches, increases the likelihood of finding a trial that matches your unique tumor genetics.
Patient Consensus: Patients note that speed is essential because glioblastoma progresses quickly, and the `washout` period between standard treatments and trial entry can be difficult. Many emphasize getting genomic testing done early before the tumor changes further.